Effects of Inhaled Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium in COPD
Study Overview
This study investigated the effects of a single inhaler containing beclometasone dipropionate, formoterol fumarate, and glycopyrronium (BDP/FF/G) on lung hyperinflation and exercise endurance in patients with chronic obstructive pulmonary disease (COPD).
Key Findings
- Participants: 106 adults with COPD were enrolled; 95 completed the study.
- Improvement in Lung Capacity: BDP/FF/G showed a significant increase in resting inspiratory capacity (IC) compared to placebo (315 mL) and BDP/FF (223 mL).
- Dynamic Lung Capacity: BDP/FF/G improved dynamic IC by 245 mL compared to placebo.
- Exercise Endurance: Patients using BDP/FF/G had an increase in exercise endurance time by 69.2 seconds compared to placebo.
- Tolerability: All treatments were well tolerated, with mild to moderate adverse events reported.
Practical Solutions and Value
BDP/FF/G provides significant benefits for patients with COPD, enhancing both lung function and exercise capacity. This can lead to improved quality of life for those affected by this condition.
Clinical Implementation
To maximize the benefits of clinical trials, tools like DocSym can help integrate research findings into everyday practice. This AI-driven platform consolidates clinical guidelines and protocols, making it easier for healthcare providers to access vital information.
Streamlined Patient Care
Our mobile applications facilitate scheduling, monitoring treatments, and telemedicine, enhancing patient management and expanding digital services. By leveraging AI, clinics can improve workflows, reduce paperwork, and ultimately enhance patient outcomes.
Learn More
Discover how we can support your practice at aidevmd.com.
